Rustin G J, Booth M, Dent J, Salt S, Rustin F, Bagshawe K D
Br Med J (Clin Res Ed). 1984 Jan 14;288(6411):103-6. doi: 10.1136/bmj.288.6411.103.
To examine the possibility that cytotoxic drugs may cause sterility or congenital malformations in the offspring of women of childbearing age who are cured of cancer a study was conducted of the obstetric histories of 445 long term survivors treated in this unit with chemotherapy for gestational trophoblastic tumours between 1958 and 1978. After completing treatment 97% of those who wished for a pregnancy (49% of all women studied) conceived and 86% had at least one live birth. All these women had received methotrexate. Of the 47 women who wished to conceive and whose combination therapy included cyclophosphamide, 37 (79%) had a live birth. Women who received three or more drugs were less likely to have a live birth than those who received methotrexate alone or with only one other drug (p less than 0.001). There was no statistically significant excess of congenital malformations. These results are strong evidence that the cytotoxic drug regimens used in this unit for treating gestational trophoblastic tumours are compatible with the preservation of fertility in most women and not associated with any increase in congenital abnormalities.
为了研究细胞毒性药物是否可能导致患癌后治愈的育龄妇女的后代出现不育或先天性畸形,我们对1958年至1978年间在本单位接受化疗治疗妊娠滋养细胞肿瘤的445名长期存活者的产科病史进行了研究。完成治疗后,97%希望怀孕的患者(占所有研究女性的49%)怀孕,86%至少有一次活产。所有这些女性都接受了甲氨蝶呤治疗。在47名希望怀孕且联合治疗包括环磷酰胺的女性中,37名(79%)有活产。接受三种或更多药物治疗的女性比仅接受甲氨蝶呤或仅与另一种药物联合治疗的女性活产的可能性更小(p<0.001)。先天性畸形没有统计学上的显著增加。这些结果有力地证明,本单位用于治疗妊娠滋养细胞肿瘤的细胞毒性药物方案与大多数女性的生育能力保留相容,且与先天性异常的增加无关。